Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 4,761 shares at $23.89 ($116K) on 2026-08-04, disclosed to the SEC on 2026-08-04.
Scheduled sale ($116k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.89 | 1,794 | $43K | 37.0% |
| 2 | $24.65 | 2,967 | $73K | 63.0% |
| Total | $24.36 avg | 4,761 | $116K | 100% |
| Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |
| NRIX | SELL | 2025-11-03 | $158K | — | Filing → |